Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 5/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.56 |
| ▸ | WDR5 | P61964 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597820 | 0.81 | CCR9 (0.72) | CCR9WDR5KDM1A | |
| SCHEMBL14458106 | 0.81 | CCR9 (0.57) | CCR9FFAR4WDR5KDM1AHDAC1 | |
| SCHEMBL7590053 | 0.81 | FFAR4 (0.59) | CCR9FFAR4WDR5HDAC1HDAC8 | |
| SCHEMBL3243266 | 0.81 | CCR9 (0.70) | CCR9FFAR4WDR5KDM1AHDAC1 | |
| SCHEMBL5597824 | 0.81 | CCR9 (0.70) | CCR9FFAR4WDR5KDM1AHDAC1 | |
| SCHEMBL28260430 | 0.77 | CCR9 (0.52) | CCR9FFAR4WDR5KDM1AHDAC1 | |
| SCHEMBL7595506 | 0.76 | FFAR4 (0.57) | CCR9FFAR4FBP1SMN1; SMN2 | |
| SCHEMBL14601694 | 0.76 | FFAR4 (0.53) | CCR9FFAR4HDAC1HDAC8PTGES2 | |
| SCHEMBL343895 | 0.76 | CCR9 (1.00) | CCR9KDM1A | |
| SCHEMBL14601699 | 0.76 | CCR9 (0.63) | CCR9FFAR4WDR5KDM1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | CCR9 3886/4885FFAR4 894/4885WDR5 600/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | CCR9 4370/4885FFAR4 2368/4885WDR5 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.